open access
Leptin serum levels in cachectic and non-cachectic lung cancer patients
open access
Abstract
Introduction: Leptin, protein taking part in body mass regulation, might play a role in cancer cachexia development. The aim of the study was to measure leptin serum levels in cachectic, non-cachectic lung cancer patients, healthy controls and to correlate leptin concentration with nutritional status markers.
Material and methods: 40 lung cancer patients were enrolled into the study: 20 with cachexia, 20 without cachexia, and 10 healthy controls. Leptin serum concentration, body mass, BMI, arm circumference and skin triceps fold thickness were measured in each subject.
Results: Serum leptin level in cachectic cancer patients was significantly lower than in non-cachectic and healthy controls. Leptin concentration correlated with body mass, arm circumference and skin triceps fold thickness.
Conclusions: Cachectic lung cancer patients have significantly lower serum leptin concentrations than non-cachectic patients and healthy controls which may suggest, that leptin does not play an important role in cancer cachexia development. Leptin levels positively correlate with good nutritional status markers. Non-cachectic lung cancer patients have similar leptin serum levels as healthy controls.
Abstract
Introduction: Leptin, protein taking part in body mass regulation, might play a role in cancer cachexia development. The aim of the study was to measure leptin serum levels in cachectic, non-cachectic lung cancer patients, healthy controls and to correlate leptin concentration with nutritional status markers.
Material and methods: 40 lung cancer patients were enrolled into the study: 20 with cachexia, 20 without cachexia, and 10 healthy controls. Leptin serum concentration, body mass, BMI, arm circumference and skin triceps fold thickness were measured in each subject.
Results: Serum leptin level in cachectic cancer patients was significantly lower than in non-cachectic and healthy controls. Leptin concentration correlated with body mass, arm circumference and skin triceps fold thickness.
Conclusions: Cachectic lung cancer patients have significantly lower serum leptin concentrations than non-cachectic patients and healthy controls which may suggest, that leptin does not play an important role in cancer cachexia development. Leptin levels positively correlate with good nutritional status markers. Non-cachectic lung cancer patients have similar leptin serum levels as healthy controls.
Keywords
lung cancer; cancer cachexia; leptin
About this articleTitle
Leptin serum levels in cachectic and non-cachectic lung cancer patients
Journal
Advances in Respiratory Medicine
Issue
Article type
Research paper
Pages
500-506
Published online
2009-11-30
Bibliographic record
Pneumonol Alergol Pol 2009;77(6):500-506.
Keywords
lung cancer
cancer cachexia
leptin
Authors
Bożena Weryńska
Monika Kosacka
Marcin Gołecki
Renata Jankowska
References (17)- Nelson KA. The cancer anorexia-cachexia syndrome. Semin Oncol. 2000; 27: 64–68.
- Kosacka M, Weryńska B, Gołecki M, et al. Występowanie oraz patogeneza zespołu jadłowstrętu i wyniszczenia nowotworowego w raku płuca. Pneumonol Alergol Pol. 2008; 76: 360–365.
- Hang Y, Proenca R, Maffei M, et al. Positional cloning of the obese gene and its human homologue. Nature. 1994; 372: 425–432.
- Meyers J, McTiernan A, Ulrich C. Leptin and immune function: integrating the evidence. Nutrition Research. 2005; 25(9): 791–803.
- Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996; 334(5): 292–295.
- Caro JF, Kolaczynski JW, Nyce MR, et al. Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet. 1996; 348(9021): 159–161.
- Prolo P, Wong ML, Licinio J. Leptin. Int J Biochem Cell Biol. 1998; 30(12): 1285–1290.
- Sato T, Meguid MM, Miyata Go, et al. Does leptin really influence cancer anorexia? Nutrition. 2002; 18(1): 82–83.
- Krzakowski M. Onkologia kliniczna. Borgis Wydawnictwo Medyczne, Warszawa 2006.
- Kosacka M, Jankowska R. Epidemiologia raka płuca. Pneumonol Alergol Pol. 2007; 75: 76–80.
- Ruhl CE, Everhart JE. Leptin concentrations in the United States: relations with demographic and anthropometric measures. Am J Clin Nutr. 2001; 74(3): 295–301.
- Simons JP, Schols AM, Campfield LA, et al. Plasma concentration of total leptin and human lung-cancer-associated cachexia. Clin Sci (Lond). 1997; 93(3): 273–277.
- Alemán MR, Santolaria F, Batista N, et al. Leptin role in advanced lung cancer. A mediator of the acute phase response or a marker of the status of nutrition? Cytokine. 2002; 19(1): 21–26.
- Tas F, Duranyildiz D, Argon A, et al. Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer. Med Oncol. 2005; 22(4): 353–358.
- Jamieson NB, Brown DJF, Michael Wallace A, et al. Adiponectin and the systemic inflammatory response in weight-losing patients with non-small cell lung cancer. Cytokine. 2004; 27(2-3): 90–92.
- Bączyk M, Gorzelińska L, Łuczak J, et al. Zespół wyniszczenia nowotworowego. Wpływ leczenia na wybrane parametry kliniczne i biochemiczne. Doniesienie wstępne Pol Med Paliat. 2005; 4: 11–16.
- Elinav E, Niv-Spector L, Katz M, et al. Pegylated leptin antagonist is a potent orexigenic agent: preparation and mechanism of activity. Endocrinology. 2009; 150(7): 3083–3091.